Thank you for sharing. On the one hand, it's grea
Post# of 148179
On the other hand, it's disappointing to see that leronlimab will probably be beaten to market by an inferior drug due to lack of funding at CYDY to pursue the indication aggressively.
Great science needs cash to fly!